Introduction {#sec1-1}
============

Intensity modulated radiation therapy (IMRT) techniques reduce dose to critical structures compared to three dimensional conformal radiotherapy (3D CRT) while maintaining conformal and homogenous dose with target volume. IMRT is different from 2D or 3D CRT, it can deliver fields of non-uniform intensity \[[@ref1]\]. However, in Volumetric Modulated Arc Therapy (VMAT) the gantry rotates around the patient while the radiation is being delivered. The dose distribution was shaped into three dynamic variables: MLC, gantry rotation speed, and dose rate. The quality of VMAT treatment delivery was comparable to IMRT with an advantage such as a shorter time and less monitor unit (MU). The initial concept of VMAT was introduced by Cedric Yu in 1995 \[[@ref2]\]. He proposed radiation treatment delivery in rotational, while the field shapes and dose weighting are being modulated. The technology started commercials in the market when Otto introduced the concept of delivering the radiation dose in a single 360º arc \[[@ref3]\]. Varian has progressive resolution optimizer (PRO) algorithm used in VMAT RapidArc treatment plan optimization, the process depends on constraints to planning target volume (PTV) and organ at risk (OAR). The algorithm will find the best solution for variation of dynamic variables such as dynamic MLC, gantry and dose rate, it has four phases with increasing resolution to deliver optimal dose distribution \[[@ref4]\].

VMAT and IMRT are some of radiation therapy techniques used widely in modern radiotherapy. In order to ensure the quality and safety of these radiation therapy techniques, procedural guidelines \[[@ref5]\], quality assurance of IMRT \[[@ref6]\] and commissioning and QA of VMAT \[[@ref7]\] are followed by some of the radiotherapy centers. The proposed procedure consists of three types of tests, the first is to test MLC position accuracy (picket fence test), the second is to evaluate the dose rate control with gantry rotation speed, and the last is to test MLC leaf speed control during VMAT delivery.

American Association of Physicists in Medicine (AAPM) Task Group (TG) 119 has been published as a guidance for testing IMRT commissioning. This document was published based on reports of Radiologic Physics Center (RPC), they showed around 28% of the institutions were involved in the head and neck (HN) IMRT dosimetry audit process failed. TG 119 describes confidence limit (CL) to evaluate treatment planning and treatment delivery for IMRT, it consists of two preliminary tests to check linac stability and five tests that similar to clinically cases \[[@ref8]\]. TG 119 guidance can be used to test the VMAT technique commissioning; Mynampati applied TG 119 on VMAT and IMRT then compared with IMRT TG 119. VMAT planning shows results almost the same and it can be compared with IMRT, an average difference of planning by point dose measurement did not exceed 2% and gamma index above 96% for VMAT and IMRT. TG 119 were useful to have confidence in the new modalities such as VMAT, but they require more study from other institutions and vendors \[[@ref9]\].

Kang evaluated patient specific quality assurance (QA) results of VMAT and IMRT following TG 119 criteria; the treatment plan evaluation VMAT is able to meet the dose goal of target volume and OARs. The evaluation of absolute and relative dose measurement, VMAT results indicate the value of point dose measurement below 3% and gamma index above 97% \[[@ref10]\]. Wen evaluated overall accuracy of VMAT RapidArc and IMRT treatment delivery for both flattening filter-free (FFF) and with flattening filter (FF) based on report of TG 119. The CLs value for both techniques were below the baseline in compared to TG 119 report \[[@ref11]\]. Thomas reported TG 119 test tool useful in order to assess the adequacy of VMAT and IMRT commissioning, it is also useful to gain confidence for physicists in the clinic while using a new modality such as VMAT and IMRT. The planning results show the dose constraint based on the measurements, clearly the CLs were well within the baseline specified in TG 119 \[[@ref12]\]. The purpose of our study was to test and evaluate commissioning accuracy of VMAT, IMRT treatment planning and dose delivery using AAPM TG 119 recommendations, also generate confidence limits for local institutions.

Material and Methods {#sec1-2}
====================

TG 119 recommendations were followed in the selection, scanning phantom, treatment planning, and treatment delivery. A solid water phantom with dimensions L x W x H (30 x 30 x 20 cm^3^) was set up to measure a point dose at 10 cm depth from the surface; it is shown in [Figure 1](#JBPE-9-395-g001.tif){ref-type="fig"}, ionization chambers were put in the center of the phantom and it was scanned in CT simulator. A two-dimensional detector array MatriXX Evolution with MultiCube phantom in a sandwich position were also scanned for planar dose measurements. The phantom was scanned using Philips Brilliance CT Big Bore 16 slices (Philips Healthcare, USA). Both of phantom images were exported directly to the TPS Eclipse to be contoured for structure target (PTV) and organ at risk (OAR); TG 119 provides structure set and it can be imported to the phantom.

![(A) Solid water phantom and CT scan image (B) MatriXX and CT scan image.](JBPE-9-395-g001){#JBPE-9-395-g001.tif}

Varian treatment planning system Eclipse (v11.0.47) and linear accelerator Clinac iX D-2300CD with 120 Millennium MLC (Varian Medical Systems, USA) were used in this study. All VMAT and IMRT treatment plans using 6 MV beam, Anisotropic Analytical Algorithm (v11.0.31) were used for 3D dose distributions calculation with 2.5 cm calculation grid size. Equipment used during measurement were an ion chamber with 3 different volumes, electrometer Dose1, 2D array MatriXX Evolution, and a water phantom (IBA Dosimetry, Germany). The AAPM TG 119 problem set consists of two preliminary tests and five commissioning tests that resemble five clinical cases.

[Figure 2](#JBPE-9-395-g002.tif){ref-type="fig"} shows an illustration of preliminary tests P1 and P2. Preliminary tests P1 consist of a simple AP-PA open field of 10 x 10 cm with a prescribed dose of 2 Gy at the isocenter of solid water phantom. Preliminary tests P2 consisting of a series of AP-PA open fields in different sizes are used to creating a stair-step dose pattern, with dose ranging from 40 cGy to 200 cGy and point dose measurements are made at isocenter using ionization chambers.

![Illustration of Preliminary (A) test P1 and (B) test P2.](JBPE-9-395-g002){#JBPE-9-395-g002.tif}

[Figure 3(A)](#JBPE-9-395-g003.tif){ref-type="fig"} shows the multi-target structures, which consist of three cylindrical targets that were stacked along the axis of rotation, each target with a length of approximately 4 cm and diameter 4 cm. Each of these targets has a different dose objective. [Figure 3(B)](#JBPE-9-395-g003.tif){ref-type="fig"} demonstrates the mock prostate structures. The prostate structure is approximately ellipsoidal, with posterior concavity, with right-left (RL), anterior-posterior (AP), and superior-inferior (SI) dimensions of 4.0 x 2.6 x 6.5 cm^3^, respectively. The prostate PTV is defined as a uniform expansion of 0.6 cm around the prostate. The rectum is a cylinder with diameter of 1.5 cm, and the bladder is 5.0 x 4.0 x 5.0 cm^3^ in the RL, AP, and SI dimensions, respectively.

![Mock of (a) multi target, (b) prostate, (c) head and neck, and (d) C-shape structures in Eclipse.](JBPE-9-395-g003){#JBPE-9-395-g003.tif}

[Figure 3(C)](#JBPE-9-395-g003.tif){ref-type="fig"} shows the mock head and neck (H&N) structures, which consists of a large central PTV with parotid glands on both side and a spinal cord. The structures for H&N case were first drawn on a scanned of an anthropomorphic phantom and then transferred to the rectangular phantom, the gap between the PTV and the spinal cord is 1.5 cm. Finally, [Figure 3(D)](#JBPE-9-395-g003.tif){ref-type="fig"} shows the C-shape structures, which consist of two structures, an outer target with radius of 3.7 cm and a central core with a 1 cm radius, the gap between the two structures is 0.5 cm.

A number of dose objectives or goals for each commissioning test were provided in TG 119. The first specific aim of this work was to develop VMAT and IMRT plans for the TG 119 structure sets. The dose objectives provided in TG 119 were used as guidelines in the treatment planning process in order to create plans that had complexity and modulation similar to the TG 119 institutions' plans. [Table 1](#T1){ref-type="table"} lists of the numbers and arrangements beam for each commissioning test, for IMRT following the recommendations in TG 119, while for VMAT 2 arc is more easier to meet the dose goal criteria.

###### 

Beam parameter setup for VMAT and IMRT.

                  Number of beam/arcs   Beam arrangement          Collimator Angle   Prescribe dose (Gy)   Dose per fraction (Gy)
  --------------- --------------------- ------------------------- ------------------ --------------------- ------------------------
  **IMRT**                                                                                                 
  Multitarget     7                     50º from anterior         5º                 50                    2
  Prostate        7                     50º from anterior         5º                 80                    2
  Head and neck   9                     40º from anterior         0º                 50                    2
  C-Shape         9                     40º from anterior         5º                 50                    2
  **VMAT**                                                                                                 
  Multitarget     2                     CCW 179-181, CW 181-179   15º                50                    2
  Prostate        2                     CCW 179-181, CW 181-179   30º                80                    2
  Head and neck   2                     CCW 179-181, CW 181-179   30º                50                    2
  C-Shape         2                     CCW 179-181, CW 181-179   30º                50                    2

Local VMAT and IMRT treatment planning results were compared with TG 119 dose goal criteria to obtain the ratio between local treatment planning and TG 119. Conformity and the homogeneity index are two analysis tools were used to evaluate dosimetric comparison of VMAT and IMRT plans. Conformity Index (CI) equal to 1 corresponds to the ideal dose coverage or high conformity. Homogeneity Index (HI) corresponds to uniformity of the absorbed-dose distribution within the target volume, usually the PTV as indicated in Equation (1), where *D~2%~* is near-maximum, *D~95%~* is near-minimum, and *D~50%~* is median absorbed doses \[[@ref13]\].

${CI} = \frac{Vol\ 95\%\ coverage\ dose}{Vol\ PTV}$ ${HI} = \frac{D_{2\%} - D_{98\%}}{D_{50\%}}$ (1)

TG 119 protocol recommended using ionization chamber and planar dose measurements to have point dose for 2D array. Three ionization chambers, each one with an active volume of 0.01, 0.13, and 0.65 cm^3^ (IBA dosimetry, Germany) calibrated by Secondary Standard Dosimetry Laboratory (SSDL) BATAN, were listed in [Table 2](#T2){ref-type="table"}. The dosimeter was used to perform a point dose measurement, a volume of 0.01, 0.13, and 0.65 cm^3^ chamber selected to measure a dose point. IAEA TRS 398 protocol was used for measuring dose at a certain depth, phantom with a thickness of 20 cm and the ionization chamber has been placed at a 10 cm depth from the phantom surface, positioned at the isocenter of the linear accelerator with SAD 100 cm. The readings of detector were corrected for polarity effects, ion recombination, pressure and room temperature. Point dose measurements were taken at two regions, high and low dose region. Point dose measurement was performed to measure the composite dose of VMAT and IMRT treatment delivery of five tests commissioning TG 119. Point doses were analyzed by using the Equation (2) where D~measured~ was measured dose, D~plan~ is a planned dose, and D~prescrip~ was a prescription dose. The dose differences are indicated as the ratio of dose subtraction between planned and measured dose to prescribed dose instead of the predicted local dose.

${dose\ diff} = \frac{D_{measured} - D_{plan}}{D_{prescrip}}$ (2)

###### 

Technical specifications of the ionization chambers used in the study.

  Ionization chamber   FC65G, S/N: 2311      CC13, S/N: 9692   CC01, S/N: 9755
  -------------------- --------------------- ----------------- -----------------
  Active volume        0.65 cm^3^            0.13 cm^3^        0.01 cm^3^
  Polarizing voltage   300 V                 300 V             300 V
  Wall material        Aluminum + Graphite   Shonka            Steel + Shonka

MatriXX Evolution 2D array detector, MultiCube phantom, and OmniPro IMRT software were used to measure composite planar dose distribution and to compare it with a planar dose of the treatment planning. Gamma index analysis was established for composite planar dose distribution. The gamma index technique, which is the standard method for planar dose verification in IMRT QA, calculates the quantity gamma for each point of interest using preselected dose difference (DD) and distance to agreement (DTA) criteria and then uses the gamma value to determine the outcome (pass-fail) of the IMRT QA. Gamma index was examined for the composite planar dose distribution, the criteria were set for 3 % DD, 3 mm DTA and 2 % DD, 2 mm DTA for IMRT (7 field and 9 field) and VMAT treatment delivery (2 arc).

In addition, the confidence limit (CL) was used as recommended and defined by TG 119. In TG 119, the 95% CL were established by fitting the gamma passing rate results to an assumed Gaussian distribution, then calculating the limit in which about 95% of all datasets fall within. New clinics can use TG 119 as a reference while commissioning their own IMRT program by using the aggregate gamma passing rates from multiple clinics and their associated 95% CLs. The CL is the sum of the absolute value of the average differences and the standard deviation of the differences multiplied by a factor of 1.96 as indicated in Equation (3).

$\left. {CL} = \middle| {mean} \middle| + {1.96\ SD} \right.$ $\left. {CL} = \middle| 100 - {mea} \middle| + {1.96\ SD} \right.$ (3)

Results and Discussions {#sec1-3}
=======================

The VMAT and IMRT dose distribution for the multi target, prostate, head and neck, and C-shape cases were shown in [Figure 4](#JBPE-9-395-g004.tif){ref-type="fig"}. It is shown that dose distribution in 95 % isodose line between VMAT and IMRT is comparable, whereas IMRT produce more dose distribution in 30 % isodose line than VMAT.

![VMAT and IMRT dose distributions for all test commissioning.](JBPE-9-395-g004){#JBPE-9-395-g004.tif}

VMAT and IMRT treatment planning dose results for five clinical tests were tabulated in [Table 3](#T3){ref-type="table"}. The table demonstrates that VMAT and IMRT treatment planning system for four clinical tests were capable to meet the dose goals criteria set by TG 119 except for C-shape hard. For C-shape hard case, IMRT PTV D~10~, Core D~10~, and VMAT Core D~10~ dose criteria could not be achieved in a local clinic as per TG 119 protocol. Since the beginning the plan goal for Core D~10~˂1000 set by TG 119 would not probably be achievable, it is for testing a treatment planning system being pushed very hard. In each of table, D~XX~ designates the minimum absorbed dose received by XX% of the total volume of interest, D30 of the rectum = 70 Gy. It means that 30% of the rectum volume receives at least 70 Gy. This is determined from the cumulative DVH and can be read off the cDVH.

###### 

VMAT and IMRT treatment plan dose goals results .

  Test/Planning parameters   Volume (cm^3^)   Plan goal (cGy)   IMRT        VMAT         AAPM TG 119 Mean (cGy)   IMRT/ TG 119   VMAT/ TG 119
  -------------------------- ---------------- ----------------- ----------- ------------ ------------------------ -------------- --------------
  **Multi target**                                                                                                               
  Central D~99~              51.6             ˃5000             5023 ± 3    5038 ± 23    4955 ± 162               1.01           1.02
  Central D~10~              ˂5300            5286 ± 5          5279 ± 4    5455 ± 173   0.97                     0.97           
  Superior D~99~             51.4             ˃2500             2514 ± 13   2527 ± 1     2516 ± 85                1.00           1.00
  Superior D~10~             ˂3500            3431 ± 11         3422 ± 44   3412 ± 304   1.01                     1.00           
  Inferior D~99~             51.5             ˃1250             1374 ± 3    1344 ± 57    1407 ± 185               0.98           0.96
  Inferior D~10~             ˂2500            2250 ± 18         2445 ± 24   2418 ± 272   0.93                     1.01           
  **Prostate**                                                                                                                   
  PTV Prostate D~95~         107.9            ˃7560             7663 ± 36   7838 ± 17    7566 ± 21                1.01           1.04
  PTV Prostate D~5~          ˂8300            8129 ± 10         8144 ± 38   8143 ± 156   0.97                     1.00           
  Rectum D~30~               20.71            ˂7000             6266 ± 44   6308 ± 49    6536 ± 297               1.00           0.97
  Rectum D~10~               ˂7500            7284 ± 27         7331 ± 43   7303 ± 15    1.01                     1.00           
  Bladder D~30~              63.59            ˂7000             4624 ± 62   5103 ± 67    4394 ± 878               0.98           1.16
  Bladder D~10~              ˂7500            5913 ± 64         6375 ± 97   6269 ± 815   0.93                     1.02           
  **Head and neck**                                                                                                              
  PTV D~90~                  721.01           5000              5072 ± 6    5037 ± 9     5028 ± 58                1.01           1.00
  PTV D~99~                  ˃4650            4856 ± 7          4880 ± 22   4704 ± 52    1.03                     1.04           
  PTV D~20~                  ˂5500            5247 ± 5          5195 ± 5    5299 ± 93    0.99                     0.98           
  Cord maximum               19.18            ˂4000             3887 ± 4    3877 ± 34    3741 ± 250               1.04           1.04
  Parotid LT D~50~           10.21            ˂2000             1927 ± 3    1874 ± 29    1798 ± 184               1.07           1.04
  Parotid RT D~50~           9.98             ˂2000             1943 ± 2    1878 ± 6     1798 ± 184               1.08           1.04
  **C-shape easy**                                                                                                               
  PTV D~95~                  283.91           5000              5016 ± 4    5012 ± 7     5010 ± 17                1.00           1.00
  PTV D~10~                  ˂5500            5351 ± 2          5340 ± 5    5440 ± 52    0.98                     0.98           
  Core D~10~                 31.54            ˂2500             2237 ± 22   2234 ± 21    2200 ± 314               1.02           1.02
  **C-shape hard**                                                                                                               
  PTV D~95~                  283.91           5000              5057 ± 32   5024 ± 3     5011 ± 165               1.01           1.00
  PTV D~10~                  ˂5500            5596 ± 53         5447 ± 4    5702 ± 220   0.98                     0.96           
  Core D~10~                 31.54            ˂1000             1558 ± 19   1420 ± 4     1630 ± 307               0.96           0.87

[Figure 4](#JBPE-9-395-g004.tif){ref-type="fig"} shows axial plane dose distributions of VMAT and IMRT plans for multi target, prostate, head and neck, and C-shape cases. The dose distributions were 30% from total dose.

[Table 4](#T4){ref-type="table"} shows comparison of VMAT and IMRT plan parameter results. It consists of conformity and homogeneity indexes, number of beams, total monitor units (MU), and MU ratio of different test cases planned for both modalities. Conformity index for VMAT and IMRT were comparable for multi-target and c-shape hard test, IMRT conformity index are higher than VMAT in prostate and c-shape easy test, the value is 0.980, 1,193 and 1.160, 1.349 for IMRT and VMAT, respectively. VMAT conformity index is higher than IMRT in the last test, with a value of 1,128 and 1,198. Homogeneity indexes (HI) show comparable results for all clinical tests, for all five test cases the HI shows value close to zero. HI indicates the ratio between the maximum and minimum dose in the target volume and the lower value indicates a more homogenous dose distribution within the target volume.

###### 

The results of treatment plan comparison between VMAT and IMRT.

                          Multi Target   Prostate   Head and Neck   C-shape easy   C-shape hard                                   
  ----------------------- -------------- ---------- --------------- -------------- -------------- ------- ------- ------- ------- -------
  **Conformity index**    1.357          1.372      0.980           1.160          1.198          1.128   1.193   1.349   1.355   1.400
  **Homogeneity index**   0.042          0.047      0.074           0.055          0.067          0.073   0.113   0.090   0.154   0.133
  **Number of beams**     7              2          7               2              9              2       9       2       9       2
  **Dose per fraction**   200            200        200             200            200            200     200     200     200     200
  **Total MU**            532            372        469             560            1374           497     1174    902     1464    985
  **MU ratio**            1.43           1          0.84            1              1.76           1       1.30    1       1.49    1

Total monitor unit (MU) comparison between volumetric modulated arc therapy and intensity-modulated radiation therapy treatment plans was made for all test cases. VMAT plans resulted in fewer MUs with the quality of treatment planning being similar or even better than IMRT for all test cases except in prostate case. Total MU for IMRT plan of all test cases were 532, 469, 1374, 1174 and 1464 for multi target, prostate, head and neck, C shape from easy one to hard respectively, while the total monitor unit in VMAT were 372, 560, 497, 902 and 985, respectively. If the total MU of VMAT plans becomes the reference; the ratios of total MU for both of plans were 1.43, 0.84, 1.76, 1.30, and 1.49 respectively for all test cases. The complexity of the plan was found to be proportional to the total MU ratio, but the increase number of total MU was lower in VMAT plan compared to IMRT plan.

The Linear accelerator output calibration for 6 MV energy was performed following IAEA TRS 398, the deviation value between the measurement and the reference value was 0.36 %. That value was within the acceptable tolerance, according to AAPM TG 142 the deviation tolerance for Linac output is 2 % \[[@ref14]\]. The result from 6 MV output calibrations can be used for implementing VMAT and IMRT treatment plan.

[Tables 5](#T5){ref-type="table"} and [6](#T6){ref-type="table"} show dose point measurements and dose variations results between planned and measured dose for preliminary test P1 and P2 using three different ion chambers: CC01, CC13, and FC65. The three chambers demonstrate dose variation below 2%. The range of dose variations in test P2: bands from - 0.03 % to 1.78 %, meanwhile the mean dose variations are 1.17 %, 0.22 % and 0.32 % for CC01, CC13, and FC65 respectively. Both of these preliminary tests revealed that the non-IMRT system was commissioned with adequate accuracy.

###### 

The point dose measurements for preliminary test P1.

  Test     Ion chamber   Planned dose (cGy)   Measured dose (cGy)   Dose variation
  -------- ------------- -------------------- --------------------- ----------------
  **P1**   CC01          200                  201.93                0.0096
  CC13     200           202.39               0.0120                
  FC65G    200           202.78               0.0139                

###### 

The point dose measurements for preliminary test P2.

  Test                          Location                     Planned dose (cGy)   CC01     CC13     FC65G                       
  ----------------------------- ---------------------------- -------------------- -------- -------- --------- -------- -------- --------
  **P2**                        1st band left of isocenter   40                   40.71    0.0178   40.08     0.0019   40.09    0.0022
  2st band left of isocenter    80                           80.78                0.0098   80.02    0.0002    80.15    0.0019   
  Pita 3 di isocenter           120                          121.39               0.0116   120.65   0.0054    120.83   0.0069   
  1st band right of isocenter   160                          161.23               0.0077   159.96   -0.0003   160.19   0.0012   
  2nd band right of isocenter   200                          202.32               0.0116   200.72   0.0036    200.78   0.0039   
  Mean dose variation           0.0117                       0.0022               0.0032                                        

[Tables 7](#T7){ref-type="table"} and [8](#T8){ref-type="table"} demonstrate dose point measurements, mean dose variations, standard deviation, and confidence limit results at high dose and low dose area of five clinical test cases for VMAT and IMRT using ionization chambers CC01, CC13, and FC65G. The prescription dose at isocenter is 200 cGy per fraction for all targets. [Table 7](#T7){ref-type="table"} shows the maximum dose variations at high dose area for IMRT are 0.87 %, -0.52 %, 0.06 % and minimum dose variations of -0.04 %, -1.1 %, -1.14 % for ion chambers CC01, CC13, FC65G were measured, respectively. The means of the dose variations of CC01, CC13 and FC65G for IMRT are 0.33 %, -0.75 %, -0.44 and standard deviations of all these measurements are 0.37 %, 0.23 %, 0.48 %, respectively. The confidence limit (CL) values related to these mean and standard deviations are 0.0106, 0.0119, and 0.0137 for CC01, CC13, and FC65G chamber respectively. For VMAT, high dose area measurements show maximum dose variations of 1.03 %, -0.003 %, -0.34 % and minimum dose variations of -0.05, -1.23, -0.157 for CC01, CC13, and FC65G chamber respectively. The confidence limit (CL) values for VMAT are 0.0147, 0.0171, and 0.0208 for CC01, CC13, and FC65G, respectively.

###### 

VMAT and IMRT doses variation, standard deviation, and CL at high dose area.

  Test                     Location                       IMRT      VMAT                                    
  ------------------------ ------------------------------ --------- --------- --------- --------- --------- ---------
  Multi target             Isocenter                      0.00003   -0.0052   0.0006    -0.0003   -0.0003   -0.0137
  Prostate                 Isocenter                      -0.0004   -0.0060   -0.0013   0.0091    -0.0123   -0.0157
  Head and neck            Isocenter                      0.0087    -0.0069   -0.0030   0.0052    -0.0110   -0.0125
  C shape (easy)           2.5 cm anterior to isocenter   0.0047    -0.0082   -0.0067   0.0103    -0.0073   -0.0053
  C shape (hard)           2.5 cm anterior to isocenter   0.0035    -0.0110   -0.0114   -0.0005   -0.0017   -0.0034
                           Mean of dose variations        0.0033    -0.0075   -0.0044   0.0048    -0.0065   -0.0101
  Standard deviation σ     0.0037                         0.0023    0.0048    0.0051    0.0054    0.0054    
  CL = \|mean\| + 1.96 σ   0.0106                         0.0119    0.0137    0.0147    0.0171    0.0208    

###### 

VMAT and IMRT doses variation, standard deviation, and CL at low dose area.

  Test                     Location                        IMRT     VMAT                                   
  ------------------------ ------------------------------- -------- --------- --------- -------- --------- ---------
  Multi target             4 cm inferior to isocenter      0.0041   -0.0042   -0.0110   0.0086   -0.0041   -0.0206
  Prostate                 2.5 cm posterior to isocenter   0.0072   -0.0146   -0.0154   0.0006   0.0142    0.0331
  Head and neck            4 cm posterior to isocenter     0.0048   -0.0066   -0.0264   0.0055   -0.0049   -0.0082
  C shape (easy)           Isocenter                       0.0067   -0.0030   -0.0029   0.0007   0.0089    0.0007
  C shape (hard)           Isocenter                       0.0043   -0.0044   -0.0077   0.0072   -0.0047   -0.0057
                           Mean of dose variations         0.0054   -0.0065   -0.0127   0.0045   0.0019    -0.0002
  Standard deviation σ     0.0014                          0.0047   0.0089    0.0037    0.0090   0.0201    
  CL = \|mean\| + 1.96 σ   0.0082                          0.0158   0.0302    0.0117    0.0195   0.0396    

[Table 8](#T8){ref-type="table"} corresponds to doses variation, standard deviation, and CL at the low dose area. The location of low dose area measurement for multi target structure sets is 4 cm inferior to the isocenter, for prostate, head and neck structure low dose area measurement are at 2.5 cm and 4 cm posterior to the isocenter, whereas the low dose area measurement for C shape easy and hard structure sets are located at isocenter. For IMRT measurements at low dose area the CL are 0.0082, 0.0158, and 0.0302, whereas for VMAT CL are 0.0117, 0.0195, and 0.0396 for ion chamber CC01, CC13, FC65G respectively.

Three ionization with various active volumes showed an increase in the CL, the larger the active volume of ion chamber was found proportional to increase the value of CL. For the target and avoidance structure, CC01 reveals the lowest CL (0.82 %, 1.06 % for IMRT and 1.17 %, 1.47 % for VMAT), whereas FC65G has the highest CL (3.02 %, 1.37 % for IMRT and 3.96 %, 2.08 % for VMAT) in low dose and high dose gradient regions. TG 119 recommended that the confidence limit value for this was 4.7 %, local CLs were within 0.047. Even though FC65G CL within TG 119 limit, there is dose variation in low dose area more than 3 % beyond the expectations set by TG 119. This volume effect of the FC65G chamber or Farmer chamber could lead to inaccurate conclusions upon clinical verification of VMAT and IMRT treatment planning, one of the causes is the lack of spatial resolution of the detector used \[[@ref15]\].

[Tables 9](#T9){ref-type="table"} and [10](#T10){ref-type="table"} show the composite gamma index analysis for all different test cases planned for both modalities in high dose and low dose area, measured a 2D array MatriXX Evolution, phantom multi cube, and analyzed OmniPro-I'MRT software, the composite gamma index analysis are compared between VMAT and IMRT in [Figure 5](#JBPE-9-395-g005.tif){ref-type="fig"}. The table contains test name, location, and % pass rate of gamma analysis for VMAT and IMRT for each test commissioning. The mean percentage of 3 %/3 mm and 2 % DD/2 mm DTA criteria for IMRT are 98.59, 95.21 (high dose area) and 97.28, 90.75 (low dose area). The standard deviations of the gamma analysis for IMRT are 1.16, 3.53 (high dose area) and 1.63, 2.28 (low dose area). The corresponding CLs are 3.68, 11.71 (high dose area) and 5.93, 13.71 (low dose area). For VMAT CL of gamma evaluation with the same IMRT analyzing, criteria are 1.44, 6.33 (high dose area) and 3.89, 7.18 (low dose area).

###### 

Gamma evaluation for VMAT and IMRT at high dose area.

  Test                           Location                       3%, 3 mm gamma pass   2%, 2 mm gamma pass           
  ------------------------------ ------------------------------ --------------------- --------------------- ------- -------
  Multi target                   Isocenter                      99.23                 99.80                 97.42   98.77
  Prostate                       Isocenter                      99.04                 99.62                 97.31   98.42
  Head and neck                  Isocenter                      99.44                 99.57                 96.81   96.30
  C shape (easy)                 2.5 cm anterior to isocenter   96.59                 99.14                 89.05   95.33
  C shape (hard)                 2.5 cm anterior to isocenter   98.65                 98.77                 95.46   95.50
                                 Overall mean                   98.59                 99.38                 95.21   96.86
  Overall Standard deviation σ   1.16                           0.42                  3.53                  1.63    
  CL = \|mean\| + 1.96 σ         3.68                           1.44                  11.71                 6.33    

###### 

Gamma evaluation for VMAT and IMRT at low dose area.

  Test                           Location                        3%, 3 mm gamma pass   2%, 2 mm gamma pass           
  ------------------------------ ------------------------------- --------------------- --------------------- ------- -------
  Multi target                   4 cm inferior to isocenter      95.63                 98.26                 89.80   94.00
  Prostate                       2.5 cm posterior to isocenter   95.43                 97.20                 89.96   94.24
  Head and neck                  4 cm posterior to isocenter     98.71                 98.66                 88.89   94.04
  C shape (easy)                 Isocenter                       97.87                 98.76                 90.42   94.92
  C shape (hard)                 Isocenter                       98.75                 96.69                 94.71   93.14
                                 Overall mean                    97.28                 97.91                 90.75   94.07
  Overall Standard deviation σ   1.63                            0.92                  2.28                  0.64    
  CL = \|mean\| + 1.96 σ         5.93                            3.89                  13.71                 7.18    

![The comparison between the gamma index map of the dose distribution for VMAT and IMRT.](JBPE-9-395-g005){#JBPE-9-395-g005.tif}

All gamma evaluation results show more than 95% data points pass the criteria of 3% DD and 3 mm DTA, but for more tight criteria 2 % DD and 2 mm DTA IMRT at the low dose area fail to meet the criteria. For the same 3 %, 3 mm criteria TG 119 result value is 12.4 (i.e. 87.6 % dose point pass the criteria) as a base line. Both of them were in line with the study of Kang et al., Wen et al., and Thomas et al. \[[@ref10]-[@ref12]\] that the AAPM TG 119 can be implemented on commissioning VMAT.

Conclusion {#sec1-4}
==========

Comparing VMAT and IMRT by AAPM TG 119 protocol along with points and composite dose measurements demonstrates adequate accuracy in delivering treatments. The ionization chamber that is smaller than a Farmer type recommended by TG 119 with 0.01 cm^3^ and 0.13 cm^3^ for IMRT point dose measurement shows the confidence limit value of below 4.2 % and dose difference 3 %, while the Farmer type chamber could not meet dose criteria of 3 % dose difference. The two-dimension detector array shows CL gamma index with criteria of 3 % / 3 mm which is below 12.4 that is a limit set of TG 119 .

The CL value from the result of measurements could be used as a reference and recommendation to evaluate the accuracy and integrity of treatment planning and treatment delivery systems of VMAT and IMRT. Planning target set by TG 119 was helpful to determine baseline IMRT commissioning and it was useful for testing of new modalities such as VMAT before clinical implementation. This study focused to develop CL to evaluate the accuracy of VMAT commissioning and increase the confidence in the implementation of complex techniques.
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